Severe anaphylactic reaction to infliximab: successful treatment with adalimumab$dreport of a case
Treatment with the anti-tumour necrosis factor alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulising Crohn's disease. Infliximab has been tolerated well, with minimal and short-lived adverse effects. The likelihood of severe reactions t...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
2004
|
| In: |
European journal of gastroenterology & hepatology
Year: 2004, Volume: 16, Issue: 6, Pages: 627-630 |
| ISSN: | 1473-5687 |
| DOI: | 10.1097/00042737-200406000-00018 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: http://dx.doi.org/10.1097/00042737-200406000-00018
|
| Author Notes: | Andreas Stallmach, Thomas Giese, Carsten Schmidt, Stefan C. Meuer, Stefan S. Zeuzem |
| Summary: | Treatment with the anti-tumour necrosis factor alpha chimeric monoclonal antibody infliximab is highly effective in the treatment of refractory and fistulising Crohn's disease. Infliximab has been tolerated well, with minimal and short-lived adverse effects. The likelihood of severe reactions to infliximab, such as acute and delayed hypersensitivity infusion reactions, is small; nevertheless, if they do occur, they are life-threatening. We report a case of an anaphylaxis-like reaction in a 22-year-old female with long-standing Crohn's disease. The patient was treated successfully with adalimumab, a fully human anti-tumour necrosis factor alpha monoclonal antibody. Follow-up demonstrated mucosal healing and normalisation of elevated pro-inflammatory cytokine transcripts. |
|---|---|
| Item Description: | Gesehen am 14.06.2021 |
| Physical Description: | Online Resource |
| ISSN: | 1473-5687 |
| DOI: | 10.1097/00042737-200406000-00018 |